(23) proposed SAA for monitoring RA disease activity in patients receiving anti-TNFα therapy, since anti-TNFα therapy reduced CRP even without reduction in disease activity, while SAA was less affected. The gene discussed is SAA2; the disease is rheumatoid arthritis.